Agile Therapeutics Strengthens Executive Leadership Team with the Appointment of Paul Korner, MD, MBA, as Chief Medical Offic...
August 17 2020 - 8:00AM
Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s
healthcare company, today announced the appointment of Paul Korner,
MD, MBA, to the position of Chief Medical Officer. Dr. Korner is a
board-certified obstetrician and gynecologist with more than 20
years of pharmaceutical and biotech industry experience, including
significant experience within women’s healthcare. He will be
responsible for supporting the commercial launch of Twirla®,
advancing the Company’s internal pipeline and evaluating external
growth opportunities. Dr. Korner will report to Al Altomari,
Agile’s Chairman and Chief Executive Officer.
"We are excited to welcome Dr. Korner to Agile
as we continue to strengthen and expand our senior leadership
team," said Al Altomari. "Dr. Korner’s private practice work and
his deep pharmaceutical experience, particularly in leading
multiple women’s health product approvals and launches, makes him a
natural fit as we continue to advance Twirla towards commercial
launch and broaden our women’s health portfolio for areas of unmet
need."
Dr. Korner has served in various leadership
positions of increasing responsibility at several global companies
focused on female reproductive health, including Solvay
Pharmaceuticals, Wyeth Research, Bayer, and Ferring
Pharmaceuticals. Dr. Korner has led more than 50 clinical trials
that include multiple engagements with the U.S. Food and Drug
Administration, European Medicines Agency, Pharmaceuticals and
Medical Devices Agency in Japan, and Health Canada.
Most recently Dr. Korner brought his clinical and development
acumen to the gene therapy space as a Senior Vice President of
Clinical Development & Medical Affairs at Axovant Gene
Therapies, Ltd.
"Agile is at the forefront of expanding
healthcare options for women, and I am thrilled to join the Company
at this important time. I look forward to supporting Agile’s
continued product development and the launch of Twirla, an
innovative and important new contraceptive option for women,” said
Dr. Korner.
Dr. Korner received his MD from the Stritch
School of Medicine at Loyola University. He also holds an MBA from
the Michael J. Coles College of Business at Kennesaw State
University. He currently serves on the Laidlaw Venture Partners
Scientific Advisory Board and the Board of Directors of Voltron
Therapeutics as an Independent Director.
About Agile Therapeutics,
Inc.Agile Therapeutics is a women's healthcare
company dedicated to fulfilling the unmet health needs of today’s
women. Our product candidates are designed to provide women
with contraceptive options that offer freedom from taking a daily
pill, without committing to a longer-acting method. Our
initial product, Twirla®, (levonorgestrel and ethinyl estradiol)
transdermal system is a non-daily prescription contraceptive.
Twirla is based on our proprietary transdermal patch technology,
called Skinfusion®, which is designed to allow drug delivery
through the skin. For more information, please visit the company
website at www.agiletherapeutics.com. The
Company may occasionally disseminate material, nonpublic
information on the Company’s website.
Follow Agile on LinkedIn and
Twitter: @AgileTher.
Contact: Matt RileyHead
of Investor Relations & Corporate
Communicationsmriley@agiletherapeutics.com
Agile Therapeutics (NASDAQ:AGRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Agile Therapeutics (NASDAQ:AGRX)
Historical Stock Chart
From Sep 2023 to Sep 2024